

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)



(10) International Publication Number
WO 2024/033329 A2

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 38/10 (2006.01)
C07K 14/47 (2006.01) A61K 38/17 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/EP2023/071868

(22) International Filing Date:

07 August 2023 (07.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2211638.8 09 August 2022 (09.08.2022) GB
2211673.5 10 August 2022 (10.08.2022) GB

(71) Applicant: **UNIVERSITY OF SHEFFIELD** [GB/GB];
Western Bank, Firth Court, Sheffield S10 2TN (GB).

(72) Inventors: **HAUTBERGUE, Guillaume**; Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ (GB). **AZZOUZ, Mimoun**; Sheffield Institute for Translational Neuroscience (SITraN),

Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ (GB). **SHAW, Pamela**; Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ (GB).


(74) Agent: **SYMBIOSIS IP LIMITED**; Innovation Centre Innovation Way, Heslington, York, GB YO10 5DG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: VIRAL VECTOR

Figure 4



(57) Abstract: The present disclosure relates to antagonists that target, directly or indirectly, Serine/Arginine Rich Splicing Factor 1 (SRSF1); viral vectors comprising a nucleic acid sequence encoding SRSF1 antagonists. The use of said vector in gene therapy for the treatment of neurodegenerative diseases such as for example Amyotrophic Lateral Sclerosis (ALS) or sporadic Amyotrophic Lateral Sclerosis which is not caused by a pathological C9ORF72 hexanucleotide repeat expansion and methods thereof are also disclosed.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*